At Medichem, we believe that every patient in Europe deserves access to essential medicines

19/06/2025

At Medichem, we believe that every #patient in #Europe deserves timely, equitable #access to essential medicines. As a manufacturer committed to European production and a long-standing member of Medicines for Europe, we support the open letter addressed to EU leaders calling for urgent action to protect medicine supply, affordability, and pharmaceutical resilience.

The last few years, marked by the COVID-19 pandemic and geopolitical tensions, have revealed just how fragile medicine supply chains can be. Europe must now act decisively to future-proof access to medicines. The proposed 5-Point Pharmaceutical Action Plan offers a realistic, actionable framework to address key threats and enable a sustainable, competitive sector.
We strongly support:
1️⃣ Swift adoption of the new EU #pharmaceutical legislation, with balanced incentives that ensure access, competition, and affordability.
2️⃣ Preserving the current regulatory exclusivity period, avoiding unnecessary extensions that would raise healthcare costs without improving outcomes.
3️⃣ Enhancing the Bolar exemption, allowing generic and biosimilar manufacturers to prepare for launch immediately after patent expiry, a vital tool to accelerate patient access.
4️⃣ Ensuring legislative coherence, particularly regarding environmental policies. Proposed measures like the Urban Wastewater Treatment Directive (UWWTD) must be aligned with medicine supply objectives to avoid unintended consequences such as steep price increases or shortages.
5️⃣Prioritizing investment in European-based #manufacturing, including dedicated support through the Critical Medicines Act and industrial funding mechanisms.

Data shows the cost of delaying competition is immense. At the same time, regulatory overlap threatens access to treatments millions rely on.

Medichem stands ready to #collaborate with national governments, EU institutions, and industry partners to build a resilient and patient-centered pharmaceutical future.

➡️ Read Medicines for Europe’s open letter: https://lnkd.in/d8kpK6W8